The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) Announces the August 2026 Launch of the Peptide Pen as Its Second Commercial Product, Following the Existing BPC-157 Transdermal Patch, Extending the Canadian Peptide Company's Product Line Into Precision Injection Delivery for the Compounded Peptide and OTC Peptide Delivery-Device Markets; The Launch Positions the Company to Address Both the Consumer-Facing Injection Convenience Segment and the Provider-Directed Compounded Peptide Prescription Segment That the July 23-24, 2026 FDA PCAC Vote (6 of 7 Peptides Recommended for the Section 503A Bulks List) Set Up for Substantial Commercial Expansion Once FDA Rulemaking Completes
The Precision Peptide Company (CSE: BPC, OTCQB: PNGAF) announced the August 2026 launch of the Peptide Pen, its second commercial product following the existing BPC-157 transdermal patch. The Peptide Pen is a precision injection delivery device for peptide administration, designed to serve both the consumer-facing injection convenience segment and the provider-directed compounded peptide prescription segment. The launch positions the Canadian peptide company to address multiple channels in the peptide delivery ecosystem: over-the-counter (OTC) peptide products where FDA regulation permits, compounded peptides prescribed by state-licensed 503A pharmacies where the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) sets up substantial commercial expansion once FDA rulemaking completes (typically 12-24 months), and precision injection dosing for adherence-sensitive peptide protocols. The device announcement extends the transdermal-plus-injectable format strategy the company has been developing since the BPC-157 transdermal patch launch. Peptide delivery devices represent a small but growing segment as the broader peptide compounding market matures through the post-PCAC regulatory pathway.